{"preliminary_commentary":{"by_channel":{"x_thread":14,"bluesky_thread":5,"podcast":3,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05870319\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"OptiTROP-Lung04","nct_id":"NCT05870319","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=optitrop-lung04-nct05870319. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":null,"label":"SKB264 by IV infusion on Days 1 and 15 of each 4-week cycle;","type":"EXPERIMENTAL"},{"description":null,"label":"pemetrexed+ carboplatin or on Day 1 of each 3-week cycle, with 4 cycles chemo","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2026-09-30","type":"ESTIMATED"},"conditions":["Non-small Cell Lung Cancer"],"enrollment":{"count":376,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"SKB264","otherNames":[],"type":"DRUG"},{"name":"Pemetrexed","otherNames":[],"type":"DRUG"},{"name":"Carboplatin","otherNames":[],"type":"DRUG"},{"name":"Cisplatin","otherNames":[],"type":"DRUG"}],"last_update":"2026-05-08","lead_sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","official_title":"A Randomized, Open-Label, Multicenter Phase 3 Study to Evaluate SKB264 Monotherapy Versus Pemetrexed in Combination With Platinum in Patients With Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutation Who Have Failed to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Therapy","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2024-07-11","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-free survival (PFS)","timeFrame":"From baseline until disease progression, death, or other protocol defined reason,up to approximately 36 months"}],"references":[{"citation":"Fang W, Wu L, Meng X, Yao Y, Zuo W, Yao W, Xie Y, Zhang Y, Cui J, Zhang Y, Li X, Zhuang W, Fang J, Wang Q, Jiang W, Li K, Bai Y, Luo Y, Ma F, Yu Y, Zheng W, Liu Z, Yang B, Ma R, Fang Y, Yang R, Jiang L, Hu J, Yang J, Diao Y, Jin X, Ge J, Yang Y, Zhang L. Sacituzumab Tirumotecan in EGFR-TKI-Resistant, EGFR-Mutated Advanced NSCLC. N Engl J Med. 2026 Jan 1;394(1):13-26. doi: 10.1056/NEJMoa2512071. Epub 2025 Oct 19.","pmid":"41124220","type":"DERIVED"}],"start_date":{"date":"2023-06-26","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients","url":"https://clinicaltrials.gov/study/NCT05870319"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/optitrop-lung04-nct05870319"}